Adaptive Biotechnologies/ADPT

$4.27

2.64%
-
1D1W1MYTD1YMAX

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Ticker

ADPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Chad Robins

Employees

790

Headquarters

Seattle, United States

ADPT Metrics

BasicAdvanced
$602.25M
Market cap
-
P/E ratio
-$1.56
EPS
1.27
Beta
-
Dividend rate

What the Analysts think about ADPT

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 5 analysts.
63.93% upside
High $10.00
Low $5.00
$4.27
Current price
$7.00
Average price target

ADPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-151.85% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$45.7M
20.58%
Net income
$-69.4M
37.97%
Profit margin
-151.85%
14.42%

ADPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.43%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.40
-$0.33
-$0.35
-$0.30
-
Expected
-$0.38
-$0.35
-$0.34
-$0.33
-$0.35
Surprise
6.16%
-4.79%
3.28%
-9.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Adaptive Biotechnologies stock

Buy or sell Adaptive Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing